Scarica l'app Stockscreener
6.31
0.63%
-0.04
Pre-mercato:
6.41
0.10
+1.58%
Precedente Chiudi:
$6.35
Aprire:
$6.31
Volume 24 ore:
1.42M
Relative Volume:
1.26
Capitalizzazione di mercato:
$326.21M
Reddito:
$170.44M
Utile/perdita netta:
$-193.88M
Rapporto P/E:
-1.6808
EPS:
-3.7541
Flusso di cassa netto:
$-126.38M
1 W Prestazione:
+11.48%
1M Prestazione:
-27.97%
6M Prestazione:
-52.41%
1 anno Prestazione:
-35.02%
Intervallo 1D:
$6.08
$6.385
Intervallo di 1 settimana:
$5.57
$6.88
Portata 52W:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
6.31 | 328.28M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
REGENXBIO to push for accelerated approval of DMD gene therapy - MSN
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook - TipRanks
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
RegenXBio’s Earnings Call Signals Pivotal Gene-Therapy Win - TipRanks
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
Gene therapy innovation gains momentum at REGENXBIO during ASGCTherapy event - Traders Union
Regenxbio slides after late-stage trial data for Duchenne therapy - MSN
Biotech REGENXBIO lines up May investor talks in New York and online - Stock Titan
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News
What's Behind Regenxbio's Recent Plunge - Kavout
REGENXBIO Inc stock (US75901B1052): gene therapy pipeline in focus after recent data update - AD HOC NEWS
REGENXBIO: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results (NASDAQ:RGNX) - Seeking Alpha
RegenXBio (RGNX) Gets a Buy from RBC Capital - The Globe and Mail
RGNX Technical Analysis & Stock Price Forecast - Intellectia AI
RGNX Maintained by B of A Securities -- Price Target Lowered to $14 - GuruFocus
Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says - Moomoo
REGENXBIO Is Maintained at Overweight by Barclays - Moomoo
RGNX Maintained by Barclays -- Price Target Lowered to $12 - GuruFocus
A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $12 to $42 - Moomoo
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $10 - Moomoo
Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings - Sahm
Discipline and Rules-Based Execution in RGNX Response - Stock Traders Daily
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval - Sahm
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty - Investing.com
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty By Investing.com - Investing.com Canada
Regenxbio posts mixed Phase III data on RGX-202 - The Pharma Letter
Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to FDA Approval - GuruFocus
REGENXBIO (RGNX) Reports Positive Data from RGX-202 Trial - GuruFocus
Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns - simplywall.st
REGENXBIO advances Duchenne gene therapy toward accelerated approval - MSN
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):